Yükleniyor... / Loading...
This study examines the effectiveness of combining Guanfacine and Lidocaine in a trigeminal nerve block for managing facial pain caused by trigeminal neuropathy. It included patients with significant persistent facial pain who had not previously had a trigeminal nerve block for pain management. It was conducted in Phase 2 and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Ability to understand and read English * History of painful trigeminal neuropathy with persistent background facial pain severity \> 5/10 on VAS * Experience pain with a score of greater than 5 on a 0-10 scale (VAS) in the previous 24 hours before procedural treatment and at the time of procedural treatment. * Eligible for trigeminal nerve block procedure and have not had a trigeminal nerve block procedure for pain management prior to the enrollment in the current study. * Able to provide informed consent. Exclusion Criteria: * Presence of a significant structural lesion (e.g., tumor) as the cause of pain as shown in at least one neuroimaging study. * Current diagnosis of fibromyalgia, temporomandibular disorders (TMD), odontogenic pain or other orofacial pain deemed unrelated to the trigeminal nerve as the origin. * Allergy or any other hypersensitivity reactions to guanfacine or lidocaine or local anesthetic of the amide type, or to both iodinated contrast and gadolinium contrast. * Females who are pregnant or breastfeeding and/or plan to become pregnant or to breastfeed during study participation. * Participation in another investigational drug study within 30 days before randomization. * Inability to understand the requirements of the study, inability to abide by the study restrictions, inability to fill out the questionnaires, or inability to return for the required treatments. * Any clinically significant medical or surgical condition that in the investigator's opinion could interfere with the administration of study drug, interpretation of study results, or compromise the safety or well-being of the subject (i.e. infection, unable to stop anticoagulants). * No reliable access to telephone service to allow for contact with study personnel.